Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS Inflammation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"VBL Therapeutics"},{"company":"SciSparc","sponsor":"The Sheba Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc to Commence a Pre-Clinical Study Using its SCI-210 Cannabidiol Based Treatment for Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"SciSparc"},{"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"SciSparc"},{"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"SciSparc"},{"company":"SciSparc","sponsor":"Soroka University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"SciSparc"},{"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"SciSparc"},{"company":"Neuromagen Pharma","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Neuromagen Pharma Announces the Approval of a NIS 1.8M Budget from the Israel Innovation Authority R&D Fund Incentive Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Neuromagen Pharma"}]

SciSparc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders

Details:

The invention relates to "Pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.

Lead Product(s): Cannabinoid,N-acylethanolamine

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 12, 2022

ASK
US

Upload
your Pipeline Activity

SciSparc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder

Details:

The trial will investigate the effect of the Company’s drug candidate SCI-210, a proprietary combination of cannabidiol (“CBD”) and CannAmide™, versus CBD monotherapy, in treating ASD.

Lead Product(s): Cannabidiol,Cannamide

Therapeutic Area: Neurology Product Name: SCI-210

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Soroka University Medical Center

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 23, 2022

ASK
US

Upload
your Pipeline Activity

SciSparc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain

Details:

SCI-160 is an investigational drug candidate is an innovative, proprietary synthetic CB2 receptor agonist created, among others, for the treatment of pain and is currently in pre-clinical studies.

Lead Product(s): SCI-160

Therapeutic Area: Neurology Product Name: SCI-160

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2022

ASK
US

Upload
your Pipeline Activity

Neuromagen Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Neuromagen Pharma Announces the Approval of a NIS 1.8M Budget from the Israel Innovation Authority R&D Fund Incentive Program

Details:

The IIA funds will be used towards advancing AGS-499, Neuromagen's lead drug candidate to IND submission and to first-in-human clinical trials which are expected during 2024.

Lead Product(s): AGS-499

Therapeutic Area: Neurology Product Name: AGS-499

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Israel Innovation Authority

Deal Size: $0.5 million Upfront Cash: Undisclosed

Deal Type: Funding March 22, 2022

ASK
US

Upload
your Pipeline Activity

SciSparc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders

Details:

USPTO granted a patent for the pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.

Lead Product(s): Tetrahydrocannabinol,N-acylethanolamines

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 04, 2022

ASK
US

Upload
your Pipeline Activity

SciSparc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SciSparc to Commence a Pre-Clinical Study Using its SCI-210 Cannabidiol Based Treatment for Epilepsy

Details:

SciSparc has entered an agreement with The Sheba Fund for Health Services and Research, to perform a pre-clinical study for the evaluation of the Company's SCI-210 drug development program.

Lead Product(s): Cannabidiol,Palmitoylethanolamide

Therapeutic Area: Neurology Product Name: SCI-210

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: The Sheba Fund

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 09, 2021

ASK
US

Upload
your Pipeline Activity

VBL Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS Inflammation

Details:

VBL Therapeutics's anti-MOSPD2 antibodies that block monocyte migration without affecting T-cells, were able to recapitulate this effect and profoundly reduced inflammation and tissue damage.

Lead Product(s): VB-601

Therapeutic Area: Neurology Product Name: VB-601

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY